These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32191540)

  • 1. An update on chemical classes targeting ERK1/2 for the management of cancer.
    Pathania S; Rawal RK
    Future Med Chem; 2020 Apr; 12(7):593-611. PubMed ID: 32191540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Bräse S; Ibrahim MAA; Nieger M; Garvalov BK; Dalby KN; Kaoud TS
    Bioorg Chem; 2019 Feb; 82():290-305. PubMed ID: 30396063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation.
    Marampon F; Ciccarelli C; Zani BM
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126017
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Ishola AA; Adewole KE
    Curr Drug Discov Technol; 2020; 17(5):725-734. PubMed ID: 31284865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitogen-activated protein kinases and Hedgehog-GLI signaling in cancer: A crosstalk providing therapeutic opportunities?
    Rovida E; Stecca B
    Semin Cancer Biol; 2015 Dec; 35():154-67. PubMed ID: 26292171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of novel 1,2-bis-quinolinyl-1,4-naphthoquinones: ERK2 inhibition, cytotoxicity and molecular docking studies.
    Aly AA; El-Sheref EM; Bakheet MEM; Mourad MAE; Brown AB; Bräse S; Nieger M; Ibrahim MAA
    Bioorg Chem; 2018 Dec; 81():700-712. PubMed ID: 30268050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations.
    Miao L; Tian H
    J Drug Target; 2020 Feb; 28(2):154-165. PubMed ID: 31340679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of potent 1,2,4-trisubstituted imidazolinone derivatives with dual p38αMAPK and ERK1/2 inhibitory activity.
    Awadallah FM; Abou-Seri SM; Abdulla MM; Georgey HH
    Eur J Med Chem; 2015 Apr; 94():397-404. PubMed ID: 25778995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.
    Ward RA; Colclough N; Challinor M; Debreczeni JE; Eckersley K; Fairley G; Feron L; Flemington V; Graham MA; Greenwood R; Hopcroft P; Howard TD; James M; Jones CD; Jones CR; Renshaw J; Roberts K; Snow L; Tonge M; Yeung K
    J Med Chem; 2015 Jun; 58(11):4790-801. PubMed ID: 25977981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
    Blake JF; Burkard M; Chan J; Chen H; Chou KJ; Diaz D; Dudley DA; Gaudino JJ; Gould SE; Grina J; Hunsaker T; Liu L; Martinson M; Moreno D; Mueller L; Orr C; Pacheco P; Qin A; Rasor K; Ren L; Robarge K; Shahidi-Latham S; Stults J; Sullivan F; Wang W; Yin J; Zhou A; Belvin M; Merchant M; Moffat J; Schwarz JB
    J Med Chem; 2016 Jun; 59(12):5650-60. PubMed ID: 27227380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.
    Jaiswal BS; Durinck S; Stawiski EW; Yin J; Wang W; Lin E; Moffat J; Martin SE; Modrusan Z; Seshagiri S
    Clin Cancer Res; 2018 Aug; 24(16):4044-4055. PubMed ID: 29760222
    [No Abstract]   [Full Text] [Related]  

  • 13. Slow inhibition and conformation selective properties of extracellular signal-regulated kinase 1 and 2 inhibitors.
    Rudolph J; Xiao Y; Pardi A; Ahn NG
    Biochemistry; 2015 Jan; 54(1):22-31. PubMed ID: 25350931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained activation of the extracellular signal-regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy.
    Tong Z; Singh G; Rainbow AJ
    Cancer Res; 2002 Oct; 62(19):5528-35. PubMed ID: 12359764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.
    Soltan OM; Shoman ME; Abdel-Aziz SA; Narumi A; Konno H; Abdel-Aziz M
    Eur J Med Chem; 2021 Dec; 225():113768. PubMed ID: 34450497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents.
    Ammar UM; Abdel-Maksoud MS; Oh CH
    Eur J Med Chem; 2018 Oct; 158():144-166. PubMed ID: 30216849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coumarins as anticancer agents: a review on synthetic strategies, mechanism of action and SAR studies.
    Thakur A; Singla R; Jaitak V
    Eur J Med Chem; 2015 Aug; 101():476-95. PubMed ID: 26188907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
    Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
    Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promising Targets in Anti-cancer Drug Development: Recent Updates.
    Kumar B; Singh S; Skvortsova I; Kumar V
    Curr Med Chem; 2017; 24(42):4729-4752. PubMed ID: 28393696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.